Healthcare & Medical Devices Global On demand · 24-48h

Global Dry Powder Inhalation Device Market Strategic Research Report

Global Dry Powder Inhalation Device Market Strategic Researc…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Dry Powder Inhalation Device Market
$1.65B2025
7.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Single Dose, Multiple Doses, Storage Type

By Application: Asthmatic, COPD, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Catalent, AptarGroup, H&T Presspart, Vectura Delivery Devices, MannKind Corporation, MicroDose Therapeutx, GSK, Novartis, AstraZeneca, Boehringer Ingelheim, Orion Pharma, ​Liquidia Technologies​, ​Teva Pharmaceutical Industries​, Chiesi​​, Hovione, Nemera, Dürr, Shanghai Huarui, Hangzhou Changxi Pharmaceutical, Suzhou Inha Medicine, Shenzhen Resproly Biopharmaceuticals

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 151 pages
Market size 2025
$1.65B
Billion USD
Forecast CAGR
7.3%
2025-2032
Forecast 2032
$2.7B
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Dry Powder Inhalation Device market size is predicted to grow from US$ 1,654 million in 2025 to US$ 2,677 million in 2032; it is expected to grow at a CAGR of 7.3% from 2026 to 2032.

A dry powder inhalation device is a medical device that drives drug powder into the respiratory tract through the patient's active inhalation. Its core design concept is to use the patient's own respiratory airflow to achieve drug delivery without propellant.

Market Concentration and Key Players:

Internationally, the market concentration of dry powder inhalers is relatively high, mainly concentrated on Europe, America and other developed countries. For example, large manufacturers such as GSK, AstraZeneca and Boehringer Ingelheim; from the domestic perspective, dry powder inhalers still have great development space in China.

Manufacturing Process and Market Trends:

The manufacturing process of dry powder inhalers revolves around drug micronization, carrier optimization and device design. The core processes include jet milling, spray drying and supercritical fluid technology, among which the new spray freeze-drying method forms amorphous powder through rapid solidification at low temperature, and combines with reverse gas chromatography to accurately control the surface energy and humidity sensitivity of the powder. The particle size of micronized drug needs to be controlled within 1-5μm to optimize lung deposition. Carriers such as lactose solve the agglomeration problem through electrostatic repulsion and anti-condensation design. The multi-dose reservoir device adopts intelligent filling line to realize efficient production of 100,000 vials per hour. For example, the Ellipta inhaler synchronizes blister foil peeling with dose counting through a precision mechanical structure, ensuring a delivered dose error rate of less than 5%.

At the market level, the global and China share increased. Drivers include a chronic obstructive pulmonary disease patient base of more than 350 million patients, an increased proportion of biologics delivery demand, and intelligent devices integrated with sensors to monitor medication compliance. In terms of technical trend, flexible electronics and 3D printing are integrated to develop curved atomizing nozzle, the detection sensitivity of graphene sensor is improved, and degradable materials reduce environmental burden. At the policy end, China has included 4 types of inhalants into medical insurance through centralized procurement policy to accelerate the process of domestic substitution, such as breaking the import monopoly of healthy budesonide suspension. In the regional market, Southeast Asia shows a super-high growth rate due to the increase of medical investment, becoming a new focus of international pharmaceutical enterprise layout.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dry Powder Inhalation Device market?

What factors are driving Dry Powder Inhalation Device market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Dry Powder Inhalation Device market opportunities vary by end market size?

How does Dry Powder Inhalation Device break out by Type, by Application?

This report presents a comprehensive overview of the global Dry Powder Inhalation Device market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Single Dose
  • Multiple Doses
  • Storage Type

Segment by Application

  • Asthmatic
  • COPD
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Dry Powder Inhalation Device market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Asthmatic, COPD, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Dry Powder Inhalation Device Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.65B
2025
Forecast
$2.7B
2032
CAGR
7.3%
2025–2032
Области
5
global
Key companies
CatalentAptarGroupH&T PresspartVectura Delivery DevicesMannKind CorporationMicroDose TherapeutxGSKNovartis
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Single DoseMultiple DosesStorage Type
By Application
AsthmaticCOPDOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Single Dose
  • 3.1.3 Multiple Doses
  • 3.1.4 Storage Type
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Asthmatic
  • 4.1.3 COPD
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Catalent
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 AptarGroup
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 H&T Presspart
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Vectura Delivery Devices
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 MannKind Corporation
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 MicroDose Therapeutx
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 GSK
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Novartis
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 AstraZeneca
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Boehringer Ingelheim
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Orion Pharma
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 ​Liquidia Technologies​
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 ​Teva Pharmaceutical Industries​
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Chiesi​​
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Hovione
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Nemera
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Dürr
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Shanghai Huarui
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Hangzhou Changxi Pharmaceutical
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Suzhou Inha Medicine
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Shenzhen Resproly Biopharmaceuticals
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Dry Powder Inhalation Device market?
The global Dry Powder Inhalation Device market is estimated at US$ 1.65 billion in 2025 (base year) and is projected to reach US$ 2.68 billion by 2032.
How fast is the Dry Powder Inhalation Device market expected to grow?
The market is expected to grow at a CAGR of 7.3% from 2026 to 2032, expanding from US$ 1.65 billion in 2025 to US$ 2.68 billion in 2032, roughly 1.6 times its base-year value.
What does the Dry Powder Inhalation Device market cover?
A dry powder inhalation device is a medical device that drives drug powder into the respiratory tract through the patient's active inhalation. Its core design concept is to use the patient's own respiratory airflow to achieve drug delivery without propellant.
How is the Dry Powder Inhalation Device market segmented by type?
By type, the market is segmented into Single Dose, Multiple Doses and Storage Type.
What are the key applications of Dry Powder Inhalation Device?
Key applications covered include Asthmatic, COPD and Other.
Which companies are profiled in the Dry Powder Inhalation Device market report?
Key players profiled include Catalent, AptarGroup, H&T Presspart, Vectura Delivery Devices, MannKind Corporation, MicroDose Therapeutx, GSK and Novartis, among 21 companies covered in total.
What geographies does the Dry Powder Inhalation Device market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Dry Powder Inhalation Device?
What factors are driving Dry Powder Inhalation Device market growth, globally and by region?
Who should buy the Dry Powder Inhalation Device market report?
The report is intended for manufacturers and solution providers, distributors and end users in Asthmatic, COPD and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Dry Powder Inhalation Device market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.